Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in Bangladesh.

Md Jahidul Hasan Raihan Rabbani Ahmad Mursel AnamShihan Mahmud Redwanul Huq

Published in: Annals of medicine (2022)

Triple-immunosuppressants in severe-to-critical COVID-19 infection exhibited better clinical outcome; reduced ICU and MV requirement; shorter hospital stay with deceased 60-day all cause mortality and re-hospitalisation compared to dual-immunosuppressants.

Keyphrases

coronavirus disease
sars cov
early onset
intensive care unit
healthcare
mechanical ventilation
acute care
adverse drug
respiratory syndrome coronavirus